Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy

We have prospectively validated in an independent clinical cohort the finding that elevated amounts of tumor-infiltrating lymphocytes in breast carcinoma tissues predict the response of patients to neoadjuvant chemotherapy. These results suggest that a robust tumor infiltration by T and B cells is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa-Nummer, Yasmin, Loibl, Sibylle, von Minckwitz, Gunter, Denkert, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203634/
https://www.ncbi.nlm.nih.gov/pubmed/25340002
http://dx.doi.org/10.4161/onci.27926
_version_ 1782340414416617472
author Issa-Nummer, Yasmin
Loibl, Sibylle
von Minckwitz, Gunter
Denkert, Carsten
author_facet Issa-Nummer, Yasmin
Loibl, Sibylle
von Minckwitz, Gunter
Denkert, Carsten
author_sort Issa-Nummer, Yasmin
collection PubMed
description We have prospectively validated in an independent clinical cohort the finding that elevated amounts of tumor-infiltrating lymphocytes in breast carcinoma tissues predict the response of patients to neoadjuvant chemotherapy. These results suggest that a robust tumor infiltration by T and B cells is a promising biomarker to define patients who might benefit from neoadjuvant chemotherapy.
format Online
Article
Text
id pubmed-4203634
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-42036342015-02-14 Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy Issa-Nummer, Yasmin Loibl, Sibylle von Minckwitz, Gunter Denkert, Carsten Oncoimmunology Author's View We have prospectively validated in an independent clinical cohort the finding that elevated amounts of tumor-infiltrating lymphocytes in breast carcinoma tissues predict the response of patients to neoadjuvant chemotherapy. These results suggest that a robust tumor infiltration by T and B cells is a promising biomarker to define patients who might benefit from neoadjuvant chemotherapy. Landes Bioscience 2014-02-14 /pmc/articles/PMC4203634/ /pubmed/25340002 http://dx.doi.org/10.4161/onci.27926 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Issa-Nummer, Yasmin
Loibl, Sibylle
von Minckwitz, Gunter
Denkert, Carsten
Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
title Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
title_full Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
title_fullStr Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
title_full_unstemmed Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
title_short Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
title_sort tumor-infiltrating lymphocytes in breast cancer: a new predictor for responses to therapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203634/
https://www.ncbi.nlm.nih.gov/pubmed/25340002
http://dx.doi.org/10.4161/onci.27926
work_keys_str_mv AT issanummeryasmin tumorinfiltratinglymphocytesinbreastcanceranewpredictorforresponsestotherapy
AT loiblsibylle tumorinfiltratinglymphocytesinbreastcanceranewpredictorforresponsestotherapy
AT vonminckwitzgunter tumorinfiltratinglymphocytesinbreastcanceranewpredictorforresponsestotherapy
AT denkertcarsten tumorinfiltratinglymphocytesinbreastcanceranewpredictorforresponsestotherapy

Ejemplares similares